Alvotech and Abdi Ibrahim Sign Biosimilar Partnership for Turkey

Alvotech and Abdi Ibrahim, a leading Turkish pharmaceutical company, have established an exclusive partnership focused on the development and commercialization of biosimilars within the Turkish market. This agreement grants Alvotech access to Turkey's rapidly expanding biosimilar sector.

Under the terms of the agreement, Alvotech will manage the development and supply of multiple biosimilar assets from its current pipeline. Abdi Ibrahim will undertake the joint manufacturing from its facilities and handle the registration and commercialization of these products in Turkey. The collaboration leverages Abdi Ibrahim's local market experience and manufacturing capabilities.

Alvotech's development pipeline includes several biosimilar monoclonal antibodies and fusion proteins targeting severe immune and inflammatory conditions. The company operates a vertically integrated platform designed to support the annual introduction of new products.

Abdi Ibrahim, founded in 1912, holds a leading position in the Turkish pharmaceutical industry. The company possesses extensive manufacturing capabilities, including for biologics, and a broad product portfolio. The partnership aims to enhance patient access to high-quality biosimilars in Turkey.